Principal Financial Group Inc. Sells 9,441 Shares of Glaukos Co. (NYSE:GKOS)

Principal Financial Group Inc. cut its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 3.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 288,505 shares of the medical instruments supplier's stock after selling 9,441 shares during the quarter. Principal Financial Group Inc. owned approximately 0.57% of Glaukos worth $37,586,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in GKOS. Oppenheimer & Co. Inc. acquired a new stake in shares of Glaukos in the first quarter worth $217,000. Swiss National Bank raised its position in Glaukos by 0.5% in the 1st quarter. Swiss National Bank now owns 91,500 shares of the medical instruments supplier's stock worth $8,628,000 after buying an additional 500 shares during the last quarter. Sei Investments Co. increased its position in Glaukos by 1.7% during the first quarter. Sei Investments Co. now owns 71,613 shares of the medical instruments supplier's stock worth $6,752,000 after acquiring an additional 1,190 shares during the period. Qsemble Capital Management LP acquired a new stake in shares of Glaukos in the 1st quarter valued at approximately $251,000. Finally, ProShare Advisors LLC lifted its holdings in Glaukos by 7.0% during the 1st quarter. ProShare Advisors LLC now owns 9,780 shares of the medical instruments supplier's stock valued at $922,000 after purchasing an additional 637 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Truist Financial upped their price target on Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a report on Monday, October 14th. StockNews.com raised Glaukos from a "sell" rating to a "hold" rating in a research note on Monday, October 21st. Stifel Nicolaus increased their price target on Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Needham & Company LLC raised their price target on shares of Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. upped their target price on Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $134.55.

Insider Buying and Selling

In related news, Director Marc Stapley sold 6,250 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the completion of the transaction, the director now owns 34,076 shares in the company, valued at $4,291,190.68. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, COO Joseph E. Gilliam sold 2,275 shares of the firm's stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $14,198,425.93. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Marc Stapley sold 6,250 shares of the company's stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the completion of the transaction, the director now directly owns 34,076 shares of the company's stock, valued at approximately $4,291,190.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,525 shares of company stock valued at $2,142,029. Corporate insiders own 6.40% of the company's stock.

Glaukos Stock Down 0.1 %

Shares of NYSE:GKOS traded down $0.11 during trading on Tuesday, reaching $142.93. 181,108 shares of the stock were exchanged, compared to its average volume of 578,306. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $145.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.67. The stock has a fifty day moving average of $130.07 and a two-hundred day moving average of $121.35. The firm has a market cap of $7.88 billion, a price-to-earnings ratio of -47.64 and a beta of 1.02.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million for the quarter, compared to analysts' expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company's quarterly revenue was up 23.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. Research analysts anticipate that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.